Skip to main content
. 2017 May 23;6(6):1233–1239. doi: 10.1002/cam4.1081

Table 3.

SM rate in the different treatment groups

Groups SM No SM Yes FU (years) median ET (years) median
No therapy 209 (95%) 11 (5%) 5 (0.1–23) NA
HU 599 (93%) 42 (7%) 6 (0.1–32) 4 (0.1–30)
ALK 24 (92%) 2 (8%) 12 (1–30) 8 (0.4–23)
ALK + HU 79 (92%) 7 (8%) 10 (2–26) 9 (0.6–24)
ANA/IFN 51 (96%) 2 (4%) 8 (2–21) 4 (0.1–20)

HU, hydroxyurea; ALK, alkylating agents; ANA, anagrelide; IFN, α‐interferon; SM, secondary malignancy; FU, follow‐up; ET, exposure time.